Literature DB >> 775613

Susceptibility of the liver and biliary tract to anaerobic infection in extrahepatic biliary tract obstruction. III. Possible synergistic effect between anaerobic and aerobic bacteria. An experimental study in rabbits.

M Lykkegaard Nielsen, S Asnaes, T Justesen.   

Abstract

The pathogenicity of single anaerobic, single aerobic, and mixed anaerobic and aerobic bacterial inocula was studied in 3 groups of 12 rabbits with biliary tract obstruction. B. fragilis, ss. fragilis and E. coli serotype 01: K1: H7 were used. The investigation was made 7 days after bacterial inoculation and included bacteriological studies of the liver and bile as well as studies of liver function and morphology of the liver and biliary tract. Inoculation of 10(5)-10(6) E. coli did not cause biliary tract infection, liver abscesses or death. Inoculation of 10(9) B. fragilis caused biliary tract infection in 83% and liver abscesses in 17% of the animals inoculated, without any mortality. Combined inoculation with B. fragilis and E. coli in reduced doses significantly increased mortality (42%) and frequency of liver abscesses in surviving animals (86%). All abscesses, however, yielded pure culture of B. fragilis only. 84% of the animals inoculated with B. fragilis alone or with B. fragilis in combination with E. coli developed biliary tract infection with B. fragilis, the bile yielding from 10(7)-10(9) B. fragilis per ml, gallbladder bile yielding significantly higher bacterial counts than common duct bile. E coli was never recovered from bile in surviving animals but from both bile and blood in animals not surviving the experimental period.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 775613

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  10 in total

1.  Aerobic and anaerobic microbiology of biliary tract disease.

Authors:  I Brook
Journal:  J Clin Microbiol       Date:  1989-10       Impact factor: 5.948

2.  Proceedings of the 20th Autumn Meeting from October 19 20, and 21, 1978--Gifu, Japan.

Authors: 
Journal:  Gastroenterol Jpn       Date:  1979-08

3.  In vitro stimulation of Bacteroides fragilis growth by Escherichia coli.

Authors:  J C Hagen; W S Wood; T Hashimoto
Journal:  Eur J Clin Microbiol       Date:  1982-12       Impact factor: 3.267

4.  The bacteriology of cholelithiasis--China versus Japan.

Authors:  R X Guo; S G He; K Shen
Journal:  Jpn J Surg       Date:  1991-11

5.  Bacteriological investigation of bile in patients with cholelithiasis.

Authors:  H Ohdan; H Oshiro; Y Yamamoto; I Tanaka; K Inagaki; K Sumimoto; T Hinoi
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

6.  Effect of anaerobic bacteria on killing of Proteus mirabilis by human polymorphonuclear leukocytes.

Authors:  F Namavar; A M Verweij; M Bal; T J van Steenbergen; J de Graaff; D M MacLaren
Journal:  Infect Immun       Date:  1983-06       Impact factor: 3.441

7.  Bacteriology of acute obstructive suppurative cholangitis of the aged.

Authors:  K Shimada; T Noro; T Inamatsu; K Urayama; K Adachi
Journal:  J Clin Microbiol       Date:  1981-11       Impact factor: 5.948

8.  Experimental intraabdominal abscess formation by Escherichia coli and bacteroides fragilis.

Authors:  J C Hagen; W S Wood; T Hashimoto
Journal:  Eur J Clin Microbiol       Date:  1983-02       Impact factor: 3.267

9.  Gangrenous cholecystitis and acute cholangitis associated with anaerobic bacteria in bile.

Authors:  C Marne; R Pallarés; R Martín; A Sitges-Serra
Journal:  Eur J Clin Microbiol       Date:  1986-02       Impact factor: 3.267

10.  Association of Microbial Dysbiosis with Gallbladder Diseases Identified by Bile Microbiome Profiling.

Authors:  Seong Ji Choi; Yeseul Kim; Jehyun Jeon; Ho Jin Gwak; Mimi Kim; Kyojin Kang; Yohan Kim; Jaemin Jeong; Yun Kyung Jung; Kyeong Geun Lee; Ho Soon Choi; Dong Hwan Jung; Sung Gyu Lee; Yangsoon Lee; Su Jin Shin; Kiseok Jang; Mina Rho; Dongho Choi
Journal:  J Korean Med Sci       Date:  2021-07-19       Impact factor: 2.153

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.